title: Monoclonal antibodies in the treatment of advanced colorectal cancer.
abstract: Despite the advances obtained in recent years in the treatment of metastatic colorectal cancer, the prognosis remains poor. An emerging understanding of the molecular pathways has provided novel targets in cancer therapy to improve these results. Emerging data from the clinical development of new drugs against these targets is providing novel opportunities in the treatment of patients with colorectal cancer. There is a need to optimize and define the best use of these new approaches. In this review, the authors examine the current development status of monoclonal antibodies in the treatment of advanced colorectal cancer.
authors.affiliation: Medical Oncology Department, Vall d'Hebron University Hospital, P. Vall d'Hebron 119-129, 08035 Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Capdevila
authors.forename: C
authors.initials: C
authors.lastname: Saura
authors.forename: T
authors.initials: T
authors.lastname: Macarulla
authors.forename: E
authors.initials: E
authors.lastname: Casado
authors.forename: F J
authors.initials: FJ
authors.lastname: Ramos
authors.forename: J
authors.initials: J
authors.lastname: Tabernero
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D009362:Neoplasm Metastasis; D000077544:Panitumumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000077544:Panitumumab; C512478:EGFR protein, human; D066246:ErbB Receptors; C520777:matuzumab; D000068818:Cetuximab